Maximus (NYSE:MMS) Upgraded at Wall Street Zen

Maximus logo with Industrials background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Maximus from “hold” to “buy,” although the broader analyst consensus remains “hold.”
  • Maximus reported quarterly EPS of $2.11, beating the roughly $1.85 analyst estimate; revenue was $1.30 billion, in line with expectations, and down 1.3% year over year.
  • Fiscal 2027 EPS guidance of $7.50–$8.00 is below the cited analyst consensus of $8.36, while the company’s revenue outlook of $5.5–$5.7 billion is above consensus.
  • Five stocks to consider instead of Maximus.

Maximus (NYSE:MMS - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued research reports about the company. Zacks Research raised Maximus from a "strong sell" rating to a "hold" rating in a research report on Thursday, October 1st. Weiss Ratings reiterated a "hold (c-)" rating on shares of Maximus in a research report on Friday, November 13th. Two investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the company currently has an average rating of "Hold".

Check Out Our Latest Report on Maximus

Maximus Trading Up 1.0%

Shares of NYSE MMS opened at $62.64 on Friday. The company's fifty day moving average is $60.19 and its 200-day moving average is $62.81. The stock has a market cap of $3.28 billion, a price-to-earnings ratio of 8.60 and a beta of 0.57. Maximus has a twelve month low of $51.04 and a twelve month high of $100.00. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 0.90.

Maximus (NYSE:MMS - Get Free Report) last released its quarterly earnings data on Thursday, November 19th. The health services provider reported $2.11 EPS for the quarter, beating analysts' consensus estimates of $1.85 by $0.26. The business had revenue of $1.30 billion during the quarter, compared to analysts' expectations of $1.30 billion. Maximus had a net margin of 7.07% and a return on equity of 24.91%. The firm's quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.62 EPS. Maximus has set its FY 2027 guidance at 7.500-8.000 EPS. Equities research analysts predict that Maximus will post 7.95 EPS for the current year.

Insider Activity

In other news, insider Michelle Link sold 3,208 shares of the business's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $54.23, for a total value of $173,969.84. Following the sale, the insider directly owned 13,881 shares in the company, valued at $752,766.63. The trade was a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Maximus during the 2nd quarter worth about $400,186,000. Dimensional Fund Advisors LP grew its stake in Maximus by 7.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,107,278 shares of the health services provider's stock valued at $135,084,000 after buying an additional 141,362 shares during the last quarter. Reinhart Partners LLC. grew its stake in Maximus by 131.8% in the 2nd quarter. Reinhart Partners LLC. now owns 1,982,415 shares of the health services provider's stock valued at $106,575,000 after buying an additional 1,127,346 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Maximus by 56.4% during the third quarter. Goldman Sachs Group Inc. now owns 1,001,596 shares of the health services provider's stock worth $53,275,000 after acquiring an additional 361,001 shares during the last quarter. Finally, Stephens Investment Management Group LLC lifted its position in Maximus by 0.5% during the third quarter. Stephens Investment Management Group LLC now owns 859,320 shares of the health services provider's stock worth $45,707,000 after acquiring an additional 4,535 shares during the last quarter. 97.21% of the stock is currently owned by institutional investors.

Maximus News Summary

Investors following MMS have been watching these news items:

  • Positive Sentiment: Fiscal Q4 adjusted earnings were $2.11 per share, above consensus estimates of roughly $1.85–$1.88 and up from $1.62 a year earlier. Revenue of $1.30 billion was in line with estimates. Maximus tops Q4 earnings estimates
  • Positive Sentiment: Management forecast fiscal 2027 revenue of $5.5 billion–$5.7 billion, above the cited $5.4 billion analyst consensus, and free cash flow of $700 million–$800 million while integrating Agile Defense. Maximus forecasts fiscal 2027 free cash flow
  • Negative Sentiment: Fiscal 2027 EPS guidance of $7.50–$8.00 was below the reported analyst consensus of $8.36, a potential near-term pressure despite the stronger revenue outlook. Maximus sees growth in fiscal 2027

About Maximus

(Get Free Report)

Maximus, Inc. provides technology-enabled services to government agencies, helping them administer public programs and deliver services to residents. Its work includes managing contact centers, processing applications and eligibility determinations, conducting health assessments, and supporting appeals and other case-management functions. The company serves clients in the United States and internationally, including government agencies in the United Kingdom, Canada and Australia. Its services span health and human services programs as well as federal government operations, with technology and digital services supporting its program work.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Maximus Right Now?

Before you consider Maximus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maximus wasn't on the list.

While Maximus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines